It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hemolysin expressing UPEC strains have been associated with severe advanced kidney pathologies, such as cystitis and pyelonephritis, which are associated with an inflammatory response. Macrophages play an important role in regulating an inflammatory response during a urinary tract infection. We have studied the role of purified recombinant α-hemolysin in inducing inflammatory responses and cell death in macrophages. Acylation at lysine residues through HlyC is known to activate proHlyA into a fully functional pore-forming toxin, HlyA. It was observed that active α-hemolysin (HlyA) induced cleavage of caspase-1 leading to the maturation of IL-1β, while inactive α-hemolysin (proHlyA) failed to do so in THP-1 derived macrophages. HlyA also promotes deubiquitination, oligomerization, and activation of the NLRP3 inflammasome, which was found to be dependent on potassium efflux. We have also observed the co-localization of NLRP3 within mitochondria during HlyA stimulations. Moreover, blocking of potassium efflux improved the mitochondrial health in addition to a decreased inflammatory response. Our study demonstrates that HlyA stimulation caused perturbance in potassium homeostasis, which led to the mitochondrial dysfunction followed by an acute inflammatory response, resulting in cell death. However, the repletion of intracellular potassium stores could avoid HlyA induced macrophage cell death. The findings of this study will help to understand the mechanism of α-hemolysin induced inflammatory response and cell death.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Delhi (North Campus), Dr. B. R. Ambedkar Center for Biomedical Research, Delhi, India (GRID:grid.8195.5) (ISNI:0000 0001 2109 4999)
2 University of Alabama At Birmingham, Department of Urology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
3 Longboat Explorers AB, SMiLE Incubator, Stem Cell Laboratory, Lund, Sweden (GRID:grid.8195.5)
4 Lund University, Department of Clinical Sciences, Section of Surgery, Malmö, Skåne University Hospital, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
5 University of Delhi (North Campus), Dr. B. R. Ambedkar Center for Biomedical Research, Delhi, India (GRID:grid.8195.5) (ISNI:0000 0001 2109 4999); Lund University, Department of Clinical Sciences, Section of Surgery, Malmö, Skåne University Hospital, Malmö, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)